Bengaluru 22°C

GARDP and Bugworks Research Collaborate to Develop New Antibiotic Compound

Gardp And Bugworks Research Collaborate To Develop New Antibiotic Compound

In a significant partnership, the Global Antibiotic Research & Development Partnership (GARDP) and Bengaluru-based Bugworks Research Inc are joining forces to co-develop a promising new antibiotic compound called “BWC0977.” This compound shows broad-spectrum antibiotic activity against multidrug-resistant bacteria, addressing life-threatening infections.


Under the agreement, GARDP will provide up to $20 million to Bugworks for the pharmaceutical and clinical co-development of BWC0977. In return, Bugworks grants GARDP manufacturing and commercialization rights for the compound in 146 low- or middle-income countries (LMICs).

According to GARDP, BWC0977 exhibits potent activity against two critical priority superbugs identified by the WHO, namely carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae. These pathogens, increasingly untreatable, accounted for over 20% of antimicrobial resistance (AMR)-associated deaths in 2019.

Manica Balasegaram, GARDP’s executive director, highlighted the novelty and potential of BWC0977 to address unmet public health needs against priority pathogens where few treatments exist.

Anand Anandkumar, co-founder and CEO of Bugworks, emphasized the goal of enabling access to this compound in both Western countries and LMICs with high AMR burden. The collaboration builds on prior funding from CARB-X to advance BWC0977 through early-stage research and initial clinical testing.

The development of BWC0977 reflects the global health ecosystem’s response to the AMR crisis, with CARB-X providing critical support for pre-clinical development and initial clinical studies. GARDP’s collaboration with Bugworks aims to further develop BWC0977 and ensure global access upon approval.


Captain Ad 32.5x25 (kannada)